Dazodalibep

Generic Name: Dazodalibep

Clinical Trials

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Phase 3

Recruiting

Conditions: Sjögren's Syndrome

Interventions: Drug: Dazodalibep

First Posted Date: 2024-12-24

Last Posted Date: 2025-05-15

Lead Sponsor: Amgen

Target Recruit Count: 844

Registration Number: NCT06747949

Locations: 🇺🇸
Bradenton Research Center Inc, Bradenton, Florida, United States
🇺🇸
Arthritis, Rheumatic & Bone Disease Associates - P, Voorhees, New Jersey, United States
🇺🇸
Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St, Gilbert, Arizona, United States

and more 2 locations

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Phase 3

Recruiting

Conditions: Sjögren's Syndrome (SS)

Interventions: Drug: Dazodalibep
Drug: Placebo

First Posted Date: 2024-02-07

Last Posted Date: 2025-05-15

Lead Sponsor: Amgen

Target Recruit Count: 435

Registration Number: NCT06245408

Locations: 🇯🇵
Chubu Rosai Hospital, Nagoya-Shi, Aiti, Japan
🇮🇹
A.O.U. Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy
🇮🇹
Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy

and more 196 locations

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Phase 3

Recruiting

Conditions: Sjogren's Syndrome

Interventions: Drug: Dazodalibep
Drug: Placebo

First Posted Date: 2023-10-27

Last Posted Date: 2025-05-15

Lead Sponsor: Amgen

Target Recruit Count: 621

Registration Number: NCT06104124

Locations: 🇺🇸
Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona, United States
🇺🇸
Arizona Research Clinic PLLC, Chandler, Arizona, United States
🇺🇸
Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln, Flagstaff, Arizona, United States

and more 243 locations

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2

Recruiting

Conditions: Lupus Nephritis

Interventions: Drug: Placebo for VIB4920
Drug: VIB4920

First Posted Date: 2022-01-21

Last Posted Date: 2024-12-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 74

Registration Number: NCT05201469

Locations: 🇺🇸
University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology, La Jolla, California, United States
🇺🇸
UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
🇺🇸
University of California, Irvine School of Medicine Division of Rheumatology, Orange, California, United States

and more 14 locations

Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor

Phase 2

Withdrawn

Conditions: Highly Sensitized Patients on Waiting List for Kidney Transplantation

Interventions: Drug: Inebilzumab+VIB4920
Drug: VIB4920
Drug: Inebilizumab

First Posted Date: 2019-11-22

Last Posted Date: 2024-06-21

Lead Sponsor: Amgen

Registration Number: NCT04174677

Locations: 🇺🇸
Reserach Site California, San Diego, California, United States
🇺🇸
Pennsylvania Reserach Site, Bethlehem, Pennsylvania, United States

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: VIB4920
Drug: Placebo

First Posted Date: 2019-11-15

Last Posted Date: 2024-12-17

Lead Sponsor: Amgen

Target Recruit Count: 78

Registration Number: NCT04163991

Locations: 🇵🇱
Research Site, Warszawa, Poland

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

Phase 2

Completed

Conditions: Sjögren's Syndrome

Interventions: Drug: VIB4920
Drug: Placebo

First Posted Date: 2019-10-16

Last Posted Date: 2025-04-30

Lead Sponsor: Amgen

Target Recruit Count: 183

Registration Number: NCT04129164

Locations: 🇬🇧
Research Site, Truro, United Kingdom
🇺🇸
Research site, Dallas, Texas, United States

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

Phase 2

Completed

Conditions: Allografts
Rejection; Transplant, Kidney
Transplant Rejection
Kidney Transplantation

Interventions: Drug: Belatacept
Drug: VIB4920
Drug: Thymoglobulin
Drug: Methylprednisolone

First Posted Date: 2019-08-06

Last Posted Date: 2024-12-27

Lead Sponsor: Amgen

Target Recruit Count: 25

Registration Number: NCT04046549

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States

and more 1 locations

A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis

Phase 1

Completed

Conditions: Adult Onset Rheumatoid Arthritis

Interventions: Drug: VIB4920
Other: Placebo

First Posted Date: 2016-05-23

Last Posted Date: 2024-12-27

Lead Sponsor: Amgen

Target Recruit Count: 57

Registration Number: NCT02780388

Locations: 🇵🇱
Research Site, Warszawa, Poland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy